Saradakutty Geetha

Saradakutty Geetha

Auto-generated profile, based on publicly available information

Saradakutty Geetha

Govt Med Coll Konni, Dept Pediat, Pathanamthitta, Kerala, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
DSDevika Shanmugasundaram
Devika Shanmugasundaram
SAShally Awasthi
Shally Awasthi
BDBhagirathi Dwibedi
Bhagirathi Dwibedi
SGS. Geetha
S. Geetha
MJManish Jain
Manish Jain
MMManoj Vasant Murhekar
Manoj Vasant Murhekar
Background: India has set a goal to eliminate measles and rubella/Congenital Rubella Syndrome (CRS) by 2023. Towards this goal, India conducted nationwide supplementary immunization activity (SIA) with measles-rubella containing vaccine (MRCV) targeting children aged between 9 months to <15 years and established a hospital-based sentinel surveillance for CRS. Reliable data about incidence of CRS is necessary to monitor progress towards the elimination goal. Methods: We conducted serosurveys in 2019–20 among pregnant women attending antenatal clinics of 6 hospitals, which were also sentinel sites for CRS surveillance, to estimate the prevalence of IgG antibodies against rubella. We systematically sampled 1800 women attending antenatal clinics and tested their sera for IgG antibodies against rubella. We used rubella seroprevalence data from the current survey and the survey conducted in 2017 among antenatal women from another 6 CRS surveillance sites to construct a catalytic models to estimate the incidence and burden of CRS. Result: The seroprevalence of rubella antibodies was 82.3% (95% CI: 80.4–84.0). Rubella seropositivity did not differ by age group and educational status. Based on the constant and age-dependent force of infection models, we estimated that the annual incidence of CRS in India was 225.58 per 100,000 live births (95% CI: 217.49–232.41) and 65.47 per 100,000 live births (95% CI: 41.60–104.16) respectively. This translated to an estimated 14,520 (95% CI: 9,225–23,100) and 50,028 (95% CI: 48,234–51,543) infants with CRS every year based on age-dependent and constant force of infection models respectively. Conclusions: Our findings indicated that about one fifth of women in the reproductive age group in India were susceptible for rubella. The estimates of CRS incidence will serve as a baseline to monitor the impact of MRCV SIAs, as well progress towards the elimination goal of rubella/CRS.

9 September 2023 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
MIMary Iype
Mary Iype
TAThekkumakara Surendran Anish
Thekkumakara Surendran Anish
GSGeetha Saradakutty
Geetha Saradakutty
PKPa Mohammed Kunju
Pa Mohammed Kunju
MSMini Sreedharan
Mini Sreedharan
SAShahanaz M Ahamed
Shahanaz M Ahamed

13 December 2022 in The Journal of Pediatric Research
Verified
Journal Article
Closed access
GPGeethanjali Pradeepchandran
Geethanjali Pradeepchandran
SJSusy Joseph
Susy Joseph
SUSusan Uthup
Susan Uthup
GSGeetha Saradakutty
Geetha Saradakutty

11 May 2024 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
RSR. Swathy
R. Swathy
RKRekha Krishnan
Rekha Krishnan
SGS. Geetha
S. Geetha

11 August 2026 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
DSDevika Shanmugasundaram
Devika Shanmugasundaram
SVSANJAY VERMA
SANJAY VERMA
STShalini Tripathi
Shalini Tripathi
BDBhagirathi Dwibedi
Bhagirathi Dwibedi
KSKuldeep Singh
Kuldeep Singh
MMManoj Vasant Murhekar
Manoj Vasant Murhekar